Home
In Data Presented at the European Association for the Study of Diabetes and NEUROdiabetis Meetings, Lexicon Pharmaceuticals Product Pilavapadin Provided Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain.   

In Data Presented at the European Association for the Study of Diabetes and NEUROdiabetis Meetings, Lexicon Pharmaceuticals Product Pilavapadin Provided Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain.   

Trick or Trade September 18, 2025

Lexicon Pharmaceuticals in the NEWS

Yesterday, September 17, 2025, Lexicon Pharmaceuticals (LXRX) announced the presentation of clinical data from the company’s Phase 2b PROGRESS study for its investigational, AAK1-inhibitor, pilavapadin, for the treatment of diabetic peripheral neuropathic pain (DPNP) at two medical meetings:

“New Promise for Painful Diabetic Neuropathy: Results from recently finished clinical trials of Pilavapadin, an oral, non-opioid . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Trick or Trade
September 18, 2025

Other Articles